ArriVent BioPharma, Inc. Common Stock
General ticker "AVBP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $752.1M (TTM average)
ArriVent BioPharma, Inc. Common Stock follows the US Stock Market performance with the rate: 54.0%.
Estimated limits based on current volatility of 2.2%: low 34.22$, high 35.75$
Factors to consider:
- Total employees count: 77 (+48.1%) as of 2025
- Top business risk factors: Operating losses, Capital shortage, Clinical trial failure, Regulatory and compliance, IP disputes
- Current price 18.9% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.67$, 29.00$]
- 2026-12-31 to 2027-12-31 estimated range: [10.93$, 24.28$]
Financial Metrics affecting the AVBP estimates:
- Negative: with PPE of -4.9 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -14.27 < Investing cash flow per share per price, % of -8.56
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
Short-term AVBP quotes
Long-term AVBP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $74.59MM | $94.31MM | $177.53MM |
| Operating Income | $-74.59MM | $-94.31MM | $-177.53MM |
| Non-Operating Income | $5.26MM | $13.82MM | $11.23MM |
| R&D Expense | $64.88MM | $79.00MM | $153.35MM |
| Income(Loss) | $-69.33MM | $-80.49MM | $-166.31MM |
| Net Income(Loss)* | $-69.33MM | $-80.49MM | $-166.31MM |
| Stockholders Equity | $-153.19MM | $257.65MM | $307.22MM |
| Assets | $163.10MM | $274.94MM | $333.17MM |
| Operating Cash Flow | $-55.84MM | $-70.21MM | $-160.59MM |
| Investing Cash Flow | $0.00MM | $-192.47MM | $-71.23MM |
| Financing Cash Flow | $42.86MM | $186.58MM | $203.06MM |
| Earnings Per Share** | $-2.17 | $-2.56 | $-4.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.